esmo: first-line erlotinib improves nsclc outcomes
Published 14 years ago • 401 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
0:58
first line treatment options for activating egfr non-small cell lung cancer | dr. alexander spira
-
7:00
expert report on neoadjuvant immune checkpoint inhibitors for nsclc
-
9:58
esmo sweden 2008: benefits of customising erlotinib therapy for nsclc.
-
10:09
esmo 2020 expert video report on long term ici outcomes in lung cancer
-
2:39
esmo 2020 highlights on 1st line lorlatinib for alk nsclc: the crown study
-
2:48
changing course and improving dismal outcomes in lung cancer: 2022 esmo florida
-
0:56
second line treatment in activating egfr non-small cell lung cancer, mariposa - 2 | onc brothers
-
0:36
esmo 2019 daily reporter - editor's picks: lung cancer
-
0:59
new standard of care treatment for egfr exon 20 non-small cell lung cancer | dr. alexander spira
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
2:47
esmo clinical practice guidelines: beyond egfr and alk
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
18:29
esmo 2023 lung cancer - chapter 2 highlights – papillon, mariposa, mariposa-2, libretto-431
-
33:07
esmo 2020: lung cancer latest
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
16:51
post esmo update on impower clinical trial in early stage nsclc
-
1:00
esmo 2023 highlights: advances in egfr lung cancer second-line therapy